DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA455234
Title:
Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs
Descriptive Note:
Annual summary rept. 1 Mar 2005-28 Feb 2006
Corporate Author:
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Report Date:
2006-03-01
Pagination or Media Count:
17.0
Abstract:
Gene therapy shows promise for treating prostate cancer and is being exploited in several clinical trials. A major hurdle is establishing a method of verifying transgene activity in situ. beta-galactosidase beta-gal was historically the most popular reporter gene for molecular biology. I have introduced a novel concept for further exploration of gene therapy using beta-galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the pro-drugs in vitro and explore growth delay in animal models. I also have developed a new beta-galactosidase molecular reporter for MRI spectra, which can be used to detection of lacZ gene expression in vivo.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE